Hjem › Tripelnegativ brystkreft › District of Columbia › Washington
Kliniske studier for Tripelnegativ brystkreft i Washington, DC
11 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt Washington (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
RekruttererObservasjonsstudie
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekruttererFase 3
- Washington Hospital Center ( Site 0098), Washington D.C.
- Holy Cross Hospital ( Site 0091), Silver Spring · 7 mi unna
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RekruttererFase 3
- Holy Cross Hospital ( Site 0069), Silver Spring · 7 mi unna
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekruttererFase 1
- Georgetown University Medical Center, Washington D.C.
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruttererFase 3
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
Rekrutterer
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekruttererFase 1
- Normunity Investigational Site, Washington D.C.
Study of XB010 in Subjects With Solid Tumors
RekruttererFase 1
- Georgetown University Medical Center, Washington D.C.
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
RekruttererFase 2
- National Institute of Health Clinical Center, Bethesda · 7 mi unna
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekruttererFase 2
- Georgetown University Medical Center, Washington D.C.
CtDNA Based MRD Testing for NAC Monitoring in TNBC
RekruttererObservasjonsstudie
- George Washington University, Washington D.C.
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andre studier i Washington
- Kreft (alle typer)58 studier
- Ikke-småcellet lungekreft55 studier
- Brystkreft46 studier
- Metastatisk kreft43 studier
- Lungekreft41 studier
- Prostatakreft38 studier
- Fedme33 studier
- Kolorektal kreft29 studier
- Kardiovaskulær sykdom28 studier
- Blærekreft26 studier
- Akut myelogen leukemi24 studier
- Eggstokkreft23 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.